Each platform, or "work cell," which dispenses highly precise volumes of specialized reagents for detecting COVID-19 antibodies, can enable production of one m point-of-care tests per week.
BioDot is operating 7 days a week to meet demand from global diagnostics manufacturers, including contract development manufacturing organizations.
Worldwide, more than 50 companies are producing or developing COVID-19 antibody tests using BioDot technology.
Lateral flow tests for COVID-19 can detect virus antibodies in blood (IgG, IgM or both).
A patient's blood sample is placed onto a pad on the test device, onto which a BioDot work cell has previously dispensed a specific sequence of reagents and controls.
While clinicians wait, roughly 15 minutes, antibodies against SARS-CoV-2 in the sample will attach to test lines and present a positive or negative result visually or through a reader.
BioDot's automated dispensing platforms are used by diagnostics manufacturers to produce high-quality COVID-19 tests rapidly and at a scale, and these companies are responsible for regulatory approvals and distribution to the point of care.
BioDot is a provider of automated, ultralow-volume, non-contact fluid dispensing platforms for R and D applications and commercial-scale manufacturing across diagnostics and life sciences, medical products and applied industrial markets.
Its technologies are integral to production of point-of-care diagnostics for infectious diseases, allergy tests and diabetes maintenance as well as veterinary medicine and environmental applications.
BioDot, founded in 1994, is based in Irvine, Calif. and has international offices in Europe and Asia.
Inimmune signs research collaboration with Boston Children's Hospital
ResVita Bio receives USD250,000 phase one Small Business Innovation Research grant from NIAID
Phase II Data of Oral Dexpramipexole Published in Eosinophilic Asthma
AllerVie Health Rebrands Southern Allergy & Asthma
Applied BioCode Inks Distribution Agreement with Medline Industries
Vedanta Biosciences Receives Fast Track Designation for VE303
KalVista Pharmaceuticals Presents Data at 13th C1-inhibitor Deficiency & Angioedema Workshop
French Ophthalmology Specialist Horus Pharma Group Launches a Nordic Subsidiary